12 Results for "

fibrin formation

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "fibrin formation" in MCE Product Catalog:

33
33 Publications Verification
Cat. No.: HY-16268
CAS No.: 4727-31-5
Synonyms: KGN
Target:  

TGF-beta/Smad

Research Areas:  

Inflammation/Immunology

Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
loading...
    loading...
33
33 Publications Verification
Cat. No.: HY-16268A
CAS No.: 1401168-39-5
Synonyms: KGN sodium
Target:  

TGF-beta/Smad

Research Areas:  

Inflammation/Immunology

Kartogenin (KGN) sodium is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin sodium induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin sodium also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin sodium is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin sodium promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-114164H
CAS No.: 9002-04-4
Synonyms: EC 3.4.21.5 (Lyophilized); Human Alpha Thrombin (Lyophilized)
Human α-Thrombin (EC 3.4.21.5; Human Alpha Thrombin) (Lyophilized) is a terminal serine protease in the coagulation cascade, as well as a potent physiological platelet agonist and fibrin-generating enzyme in vivo. Human α-Thrombin catalyzes the conversion of fibrinogen to fibrin for blood clot formation, and activates platelet aggregation by cleaving the protease-activated receptors PAR1 (major) (Kd = 1 nM) and PAR4 (minor) on the platelet surface to expose tethered ligands. Human α-Thrombin also amplifies coagulation via positive feedback by activating coagulation factors V, VIII, XI (FV/FVIII/FXI), and switches to activate protein C to exert anticoagulant effects after binding to thrombomodulin .
This product is in a freeze-dried form.
loading...
    loading...
Cat. No.: HY-P991029
CAS No.: 2933972-64-4
Synonyms: HMB-001
Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia .
loading...
    loading...
Cat. No.: HY-P4721
CAS No.: 131791-98-5
Target:  

Thrombin

Research Areas:  

Cardiovascular Disease

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a KD < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .
loading...
    loading...
Cat. No.: HY-177804
Target:  

Thrombin

Research Areas:  

Inflammation/Immunology

Thrombin aptamer is a 11mer-DNA aptamer that targets thrombin. Thrombin aptamer inhibites thrombin-catalysed fibrin-clot formation in vitro
loading...
    loading...
Cat. No.: HY-11090A
CAS No.: 292135-59-2
DPC423 is a selective and orally active factor Xa inhibitor with a Kis of 0.15 (human) and 0.3 (rabbit) nM. DPC423 exhibits Kis of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 can be used for the study of anticoagulation of arterial thrombosis .
loading...
    loading...
Cat. No.: HY-11090
CAS No.: 209957-47-1
DPC423 free base is a selective and orally active factor Xa inhibitor with a Kis of 0.15 (human) and 0.3 (rabbit) nM. DPC423 free base exhibits Kis of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 free base blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 free base can be used for the study of anticoagulation of arterial thrombosis .
loading...
    loading...
Cat. No.: HY-P3082
CAS No.: 126053-71-2
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .
loading...
    loading...
Cat. No.: HY-P2102
CAS No.: 204641-27-0
Target:  

Thrombin

Research Areas:  

Cardiovascular Disease

BCH-2763 is a potent and selective Thrombin inhibitor. BCH-2763 has a very high affinity for thrombin (Ki = 0.11 nM). BCH-2763 can effectively inhibit fibrin formation, platelet aggregation, and free thrombin activity. BCH-2763 can be used for the study of thrombosis .
loading...
    loading...
Cat. No.: HY-19220
CAS No.: 167843-21-2
Target:  

Thrombin

Research Areas:  

Cardiovascular Disease

S-18326 is an orally active direct thrombin inhibitor. S-18326 inhibits thrombus formation by reversibly and with high affinity binding to the active site of thrombin, directly preventing the conversion of fibrinogen to fibrin. S-18326 effectively prolongs various clotting times in human plasma. S-18326 has demonstrated antithrombotic efficacy in multiple animal models without causing thrombocytopenia. S-18326 can be used in research on thromboembolic diseases .
loading...
    loading...
Cat. No.: HY-L136
1,510 compounds

Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation.

Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process.

MCE supplies a unique collection of 1,510 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

  • 1